Skip to main content
medichelpline
Join Free
Back to Drug Index
General MedicationsOPHTHALMICGeneric

BRIMONIDINE TARTRATE

BRIMONIDINE TARTRATE

Standard Dose
0.15%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued

Key Takeaways

  • Primary indication: Review priority: STANDARD Marketing status: Discontinued
  • Approval overview BRIMONIDINE TARTRATE is listed in Drugs@FDA under application 216772 (ANDA).
  • Review priority: STANDARD Marketing status: Discontinued Active ingredient BRIMONIDINE TARTRATE Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.15% Sponsor UPSHER SMITH LABS Submission history Latest submission status date: 2024-06-12 00:00:00.

Structured Monograph

Clinical summary

Approval overview BRIMONIDINE TARTRATE is listed in Drugs@FDA under application 216772 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BRIMONIDINE TARTRATE Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.15% Sponsor UPSHER SMITH LABS Submission history Latest submission status date: 2024-06-12 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.